Large-Scale Isolation of CD34+ Cells Using the Amgen Cell Selection Device Results in High Levels of Purity and Recovery
I. Mcniece, R. Briddell, G. Stoney, B. Kern, K. Zilm, D. Recktenwald, S. Miltenyi
Journal Of Hematotherapy 6:5-11 (1997)
The Amgen Cell Selection Device (ACSD) is a fully automated system based on the research scale magnetic-activated cell separation (MACS) system (Miltenyi Biotech GmbH, Bergisch Gladbach, Germany) for the selection ofCD34+ cells. Leukapheresis products (LP) (n = 30) from normal donors mobilized with recombinant human granulocyte colony-stimulating-factor (rhG-CSF) were selected with the ACSD to evaluate the performance of this system.
The starting LP contained a median of 0.51 % CD34+ cells (range 0.21 % - 1.54%) and a median WBC count of 3.0 x 1010(range 1-4.7 x 1010 cells). After selection on the ACSD a mean purity of 91.5% ± 0.6% CD34+ cells was obtained, with a median purity of 95.5% CD34+ cells.
A median of 98 x•106 total CD34+ cells were recovered post selection, with a range of 31-323 x 106 cells collected from the LP. This represented a mean recovery of 81.7% ± 6% of CD34+ cells and a median of 78% compared with starting CD34+ cell numbers in the LP.
FACS analysis of the selected products demonstrated a 4-5 log depletion of T cell subsets, including CD3, CD4, CD8, and CD56 subsets.
These data demonstrate the high performance obtained with the ACSD resulting in a final product of greater than 90% purity of CD34+ cells.
CD34+ cells selected with the ACSD represent an ideal product for clinical applications, such as tumor cell purging, T cell depletion Cor allogeneic transplant, ex vivo expansion, and gene therapy.